Copay help by condition · Digestive and liver · read 2026-11-08

Congenital Sucrase-Isomaltase Deficiency: which charitable copay funds are open

1 fund for Congenital Sucrase-Isomaltase Deficiency says it is open right now, of the 1 we hold (read 2026-11-08).

Open: Congenital Sucrase-Isomaltase Deficiency from HealthWell Foundation. Eligibility is each fund's own rule.

If you have Medicare Part D: CMS prints the annual out-of-pocket threshold as $2,400 in 2027 ($2,100 in 2026) (Table V-2 of its CY 2027 announcement). It is a benefit parameter and applies to covered drugs under plan rules. What changes on January 1.

Swipe to read across

Funds we hold for Congenital Sucrase-Isomaltase Deficiency, by the status each page gave on the day we read it.

What this is not. A record of what fund pages and FDA labels say, not advice and not a check of whether you qualify. US funds only. This page covers charitable funds from the organizations we read, the costs around a condition those funds pay for, and the drugs whose FDA label names the condition. A label naming a condition is not a statement that the drug is approved, effective or covered for you.

A copy for a patient, a clinic or a pharmacist, with each source and the date we read it.

Every fund we hold for Congenital Sucrase-Isomaltase Deficiency

OpenCongenital Sucrase-Isomaltase Deficiency

HealthWell Foundation · read 2026-11-08

Award level: not statedInsurance supported: not stated

The page lists the fund as Open. Source page

Drugs whose FDA label names Congenital Sucrase-Isomaltase Deficiency

1 drug. Each row quotes the sentence of the drug's FDA label (Indications and Usage, openFDA) that names the condition. A label naming a condition is not a statement that the drug is approved, effective or covered for you. Dashes in quotes are shown as hyphens. Of these, 0 have a program (in our assistance finder or on the program's own page) and 0 have a Medicare negotiated price in the CMS file; an empty cell says we found nothing in our data, not that nothing exists.

Drug	What the FDA label says	Manufacturer program	Medicare negotiated price
Sucraid Sacrosidase	Sucraid ® (sacrosidase) Oral Solution is indicated for the treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), in adult and pediatric patients 5 months of age and older. Label on openFDA, read 2026-11-10	not in our assistance finder	not in the CMS negotiated-price file

No broader or more specific condition page for this one.

Group: Digestive and liver. All conditions: the condition index. Fund board for every condition: charitable copay fund status.

What changed

First read on 2026-11-08. We keep each read with its date, so a fund reopening or closing will show here as a change. Until we have a second read there is nothing to compare, and we do not guess. The read date of every source is on the changes page.

This page as data

The same facts as JSON, each fund with its source URL and read date: congenital-sucrase-isomaltase-deficiency.json. Edition 2026-11, root 006ab9a329709cbe. See the licence page.

Questions

Is there an open charitable copay fund for Congenital Sucrase-Isomaltase Deficiency?

As read on 2026-11-08, 1 of the 1 funds we hold for Congenital Sucrase-Isomaltase Deficiency say they are open: Congenital Sucrase-Isomaltase Deficiency from HealthWell Foundation. Funds open and close, so check the source page before you apply.

Which organizations run funds for Congenital Sucrase-Isomaltase Deficiency?

HealthWell Foundation. Each fund row on this page links to the organization's own page.

Does an open fund mean I qualify?

No. A status says whether a fund is taking applications. Eligibility, award level and which insurance it supports are each fund's own rules; where the page states them they are shown on the fund.

How current is this page?

Statuses are what each fund's own page said on the date we read it (2026-11-08). We do not promise a fund is still in that state today.